Emyria posts record half-year as payer support fuels national Empax clinic rollout

Emyria Ltd ( (AU:EMD) ) has issued an announcement.

Emyria reported a record half-year to 31 December 2025, with revenue rising 136% to $1.55 million, driven by the expansion of its Empax mental health clinic network and the start of insurer-funded treatments in multiple states. The company remains loss-making as it invests in national expansion and clinical workforce, but expects per-clinic costs to moderate as scale and operational leverage improve.

Support from payers strengthened as Medibank expanded funding for Emyria’s treatment-resistant depression and PTSD programs nationally and the Department of Veterans’ Affairs agreed to fund eligible veterans, creating dual reimbursement pathways. With $10.5 million in cash following an institutional placement, national awards for clinical excellence, strong early patient demand and promising long-term PTSD outcomes, Emyria says it is well positioned to accelerate its Empax rollout and build a data-driven innovation pipeline in 2026.

The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.

More about Emyria Ltd

Emyria Ltd is an Australian healthcare company focused on developing and delivering innovative mental health treatments. The company operates its Empax clinic network across Western Australia, Queensland and Victoria, targeting conditions such as treatment-resistant depression and post-traumatic stress disorder, with a capital-light, hospital-integrated rollout model and growing support from private and government payers.

Average Trading Volume: 1,572,845

Technical Sentiment Signal: Hold

Current Market Cap: A$42.75M

Find detailed analytics on EMD stock on TipRanks’ Stock Analysis page.